Mechanisms Potentially Contributing to the Reduction in Mortality Associated With Ticagrelor Therapy
Author:
- David J. SchneiderDSDavid J. Schneider
Abstract
No abstract availableKeywords
Funding Information
- Johnson & Johnson
- Bayer Pharmaceuticals
- The Medicines Company
- Sanofi-Aventis
- Bristol-Myers Squibb
This publication has 16 references indexed in Scilit:
- Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass SurgeryJACC, 2011
- Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or ClopidogrelClinical Cardiology, 2010
- Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12receptor antagonistExpert Review of Cardiovascular Therapy, 2010
- Transfusion of red blood cells: the impact on short-term and long-term survival after coronary artery bypass grafting, a ten-year follow-upInteractive CardioVascular and Thoracic Surgery, 2010
- Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery DiseaseCirculation, 2009
- Prognostic Impact of Periprocedural Bleeding and Myocardial Infarction After Percutaneous Coronary Intervention in Unselected PatientsJACC: Cardiovascular Interventions, 2009
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Prognostic impact of major bleeding in patients with acute coronary syndromes.A systematic review and meta-analysisEuroIntervention, 2007
- Young thrombocytes initiate the formation of arterial thrombi in zebrafishBlood, 2005